RxDoctor Payments Data

Heather Patz, PA

Physician Assistant · Los Alamitos, CANPI 1255573234

Payments from drug & device makers

$16,500in general payments, 2019–2025

Across 460 payments — averaging $35.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Johnson & Johnson$2K
  • LNHC, Inc$1K
  • Incyte Corporation$863
  • LEO Pharma Inc.$811
  • Sanofi$802
  • plus $6K from 27 others

What the payments were for

  • Consulting fees$4,98030%
  • Speaking & faculty fees$1,2007%
  • Travel & lodging$20%
  • Food & beverage$9,89460%
  • Education$4253%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,500 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$73,086
Medicare patients
233
Services billed
1,304

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab36$134,549
OpzeluraRuxolitinib Phosphate21$40,229
ZoryveRoflumilast23$19,800
Tacrolimus38$4,107
Fluocinonide102$2,907
Tretinoin36$2,092
Metronidazole23$1,762
Ketoconazole106$1,434
Clobetasol Propionate22$876
Betamethasone Dipropionate28$799
Mometasone Furoate42$779
Clindamycin Phosphate19$767
Ciclopirox25$757
Triamcinolone Acetonide57$600
Doxycycline Monohydrate35$499

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$863$40,22921 claims
Arcutis Biotherapeutics, Inc.Zoryve$462$19,80023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Los Alamitos

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →